Valuation: Gennex Laboratories Limited

Market Cap 2.45B 25.6M 22.47M 21.22M 19.34M 36.2M 36.45M 254M 98.34M 1.25B 96.12M 94.04M 4.03B P/E 2025
15.4x
P/E 2026 8.26x
Enterprise Value 2.87B 29.98M 26.31M 24.84M 22.64M 42.38M 42.69M 297M 115M 1.47B 113M 110M 4.72B EV / Sales 2025
1.79x
EV / Sales 2026 1.25x
Free-Float
63.52%
Yield 2025 *
-
Yield 2026 -
08-14 Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
05-30 Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-14 Gennex Laboratories Limited Resignation of Shilpa Bung, Non-Executive Independent Women Director, Effective February 14, 2026 CI
02-14 Gennex Laboratories Limited Appoints Khushbu Kachhawa as Additional Director (Non-Executive Independent Women Director) CI
02-14 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
11-14 Gennex Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
14/08/25 Gennex Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
30/05/25 Gennex Laboratories Limited Announces Resignation of Dr. Sch Dharma Rao as Non-Executive Non-Independent Director, Effective May 30, 2025 CI
30/05/25 Gennex Laboratories Limited Appoints Sandeep Kumar Daga as Non-Executive Non-Independent Director CI
30/05/25 Gennex Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
14/02/25 Gennex Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
14/02/25 Gennex Laboratories Limited Announces Resignation of Mohammed Khaleequr Rahman as Non-Executive Non-Independent Director CI
14/11/24 Gennex Laboratories Limited Approves the Appointment of Akkali Santosh Kumar as Chief Financial Officer CI
1 day-0.49%
1 week-1.66%
Current month-19.97%
1 month-16.67%
3 months-5.78%
6 months+18.68%
Current year-29.37%
1 week 10.01
Extreme 10.01
10.65
1 month 10
Extreme 10
13.25
Current year 7.05
Extreme 7.05
14.77
1 year 7.05
Extreme 7.05
17.25
3 years 7.05
Extreme 7.05
29
5 years 4.81
Extreme 4.81
29
10 years 1.32
Extreme 1.32
29
Manager TitleAgeSince
Chief Executive Officer 40 17/05/2012
Director of Finance/CFO - 11/11/2024
Compliance Officer 62 19/04/2023
Director TitleAgeSince
Chairman 40 -
Director/Board Member - 20/12/2020
Director/Board Member - 20/12/2020
Change 5-day change 1-year change 3-year change Capi.($)
-0.49%-1.66%-14.48%+23.77% 25.6M
+0.13%+2.65%+63.34%+115.17% 1,055B
+0.20%+0.46%+50.92%+70.56% 654B
-0.29%+0.14%+19.82%+71.75% 467B
-0.85%+0.98%+42.13%+44.64% 348B
+0.71%+4.08%+21.75%+28.83% 275B
+1.23%+0.42%+14.11%+12.43% 258B
+2.11%+7.51%+51.88%+54.11% 224B
+0.83%+0.55%+34.64%+99.83% 187B
0.00%-10.14%-27.40%-61.08% 171B
Average +0.36%+0.50%+25.67%+46.00% 363.84B
Weighted average by Cap. +0.27%+1.32%+40.43%+68.21%

Financials

2025 2026
Net sales 1.38B 14.39M 12.63M 11.92M 10.87M 20.34M 20.49M 143M 55.27M 705M 54.02M 52.85M 2.26B 1.73B 18.02M 15.82M 14.94M 13.61M 25.48M 25.66M 179M 69.23M 882M 67.67M 66.21M 2.84B
Net income 181M 1.89M 1.66M 1.57M 1.43M 2.67M 2.69M 18.75M 7.26M 92.58M 7.1M 6.95M 298M 210M 2.19M 1.92M 1.81M 1.65M 3.09M 3.12M 21.71M 8.41M 107M 8.22M 8.04M 344M
Net Debt -275M -2.87M -2.52M -2.38M -2.17M -4.05M -4.08M -28.43M -11.01M -140M -10.76M -10.53M -451M 420M 4.38M 3.84M 3.63M 3.31M 6.19M 6.23M 43.41M 16.81M 214M 16.43M 16.08M 689M
Logo Gennex Laboratories Limited
Gennex Laboratories Limited is an India-based active pharmaceutical ingredient manufacturing company. The Company is engaged in the business of manufacturing of bulk drugs and intermediaries. It offers products in various therapeutic categories, including expectorant (mucolyte), relaxant (skeletal muscle relaxant), antihistamines, urinary tract analgesic, antifungals called triazoles, tricyclic antidepressant, acting muscle relaxants, muscle relaxant, selective serotonin reuptake inhibitors (SSRIS), and xanthine oxidase inhibitors. Its products include Guaifenesin, Methocarbamol, Fexofenadine Hcl, Phenazopyridine Hcl, Fluconazole, Melitracen Hcl, Mephenesin, Chlorphenesin, Sertraline Hcl and Allopurinol. The Company has manufacturing facilities in India which cater to both domestic and international markets. Its international markets include Bangladesh, Bolivia, China, Colombia, Costa Rica, Cuba, Germany, Indonesia, Iran, Iraq, Israel, Jordan, Kenya, South Korea, Malaysia and Mexico.
Employees
125
Date Price Change Volume
25/09/26 ₹10.10 -0.49% 195,686
24/09/26 ₹10.15 -1.65% 166,542
23/09/26 ₹10.32 +1.08% 151,130
22/09/26 ₹10.21 -0.68% 112,122
21/09/26 ₹10.28 +0.10% 315,294
  1. Stock Market
  2. Stocks
  3. GENNEX6 Stock